Inhibikase Therapeutics, Inc.

NASDAQ:IKT

Biotechnology

Healthcare
$1.30 +3.57%

+$0.06 today

Market cap
$182.35M
Beta
0.97
P/E (TTM)
-3.4
EPS (TTM)
-$0.52
52W Low $1.33High $2.26

Volume 0.50M

Average 1.03M

Balance Sheet

Inspect the capital base behind the business.

Assets

$181.20M

FY 2025 · Annual

+83.8% YoY

Liabilities

$8.30M

FY 2025 · Annual

+122.3% YoY

Equity

$172.90M

FY 2025 · Annual

+82.3% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents40.75M7.19M9.17M56.49M139.22M
Short-term Investments015.86M4.09M41.05M39.54M
Net Receivables110.14K39.88K000
Inventory00000
Other Current Assets107K1.12M739.18K106.31K343.37K
Total Current Assets42.47M24.37M14.21M98.45M180.11M
Property, Plant & Equipment (Net)0565.18K295.6K148.54K0
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00001.1M
Total Non-current Assets0565.18K295.6K148.54K1.1M
Total Assets42.47M24.94M14.51M98.6M181.2M
Account Payables1.09M1.15M646.77K943.02K1.16M
Short-term Debt248.91K0381.78K00
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00635.45K06.32M
Total Current Liabilities4.05M3.7M3.44M3.73M8.3M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities0205.45K90.12K00
Total Liabilities4.05M3.9M3.53M3.73M8.3M
Common Stock25.16K4.22K6.19K69.36K131.69K
Retained Earnings(29.82M)(47.87M)(66.9M)(94.42M)(142.68M)
Accumulated OCI0104.72K877(37.25K)21.8K
Other Stockholders Equity0007770
Minority Interest00000
Total Equity38.42M21.04M10.98M94.87M172.9M
Total Debt248.91K351.29K622K110.52K0
Net Debt(40.5M)(6.84M)(8.54M)(56.38M)(139.22M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$49.6M
Short-term Investments$120.8M
Other Current$1.8M
Total Current Assets$172.2M
Other Non-current$1.2M
Total Non-current Assets$1.2M
Total Assets$173.3M

Analysis

Selected assets total $173.3M for Latest. The largest visible component is Short-term Investments at $120.8M, about 69.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
4Statement of changes in beneficial ownershipOct 21, 2026
3Initial statement of beneficial ownershipOct 21, 2026
8-KCurrent reportOct 20, 2026

How much cash does IKT have?

Inhibikase Therapeutics, Inc. (IKT) reported $139.22M in cash and equivalents in fiscal 2025.

How much debt does IKT carry?

Inhibikase Therapeutics, Inc. (IKT) reported $0.00 of total debt, with net debt of -$139.22M.